Expression and prognostic value of c-Myc and Fas (CD95/APO1) in patients with pancreatic cancer

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 2, 2014, Pages 751-759

  He, Chengzhi ^a   Jiang, Hua ^a   Geng, Shasha ^a   Sheng, Haihui ^b   Shen, Xiaoying ^b   Zhang, Xiaoyan ^b   Zhu, Shizhang ^b   Chen, Ximei ^a   Yang, Changqing ^a   Gao, Hengjun ^a,b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b National Engineering Center for Biochip   (China)

Author keywords

C Myc; Fas (CD95 APO1); Immunohistochemistry; Pancreatic cancer; Survival analysis

Indexed keywords

EID: 84894044827     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Jemal A, Siegel R, Xu JQ and Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Bond-Smith G, Banga N, Hammond TM and Imber CJ. Pancreatic adenocarcinoma. BMJ 2012; 344: e2476.
3. Gong ZH, Holly EA and Bracci PM. Survival in Population-based Pancreatic Cancer Patients: San Francisco Bay Area, 1995-1999. Am J Epidemiol 2011; 174: 1373-1381.
4. Mitchem JB, Hamilton N, Gao F, Hawkins WG, Linehan DC and Strasberg SM. Long-Term Results of Resection of Adenocarcinoma of the Body and Tail of the Pancreas Using Radical Antegrade Modular Pancreatosplenectomy Procedure. J Am Coll Surg 2012; 214: 46-52.
5. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PWT, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL and Wolff RA. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26: 3496-3502.
6. Vincent A, Herman J, Schulick R, Hruban RH and Goggins M. Pancreatic cancer. Lancet 2011; 378: 607-620.
7. Hammad N, Heilbrun LK, Philip PA, Shields AF, Zalupski MM, Venkatramanamoorthy R and El-Rayes BF. CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy. Asia Pac J Clin Oncol 2010; 6: 98-105.
8. Dabritz J, Preston R, Hanfler J and Oettle H. Follow-Up Study of K-ras Mutations in the Plasma of Patients With Pancreatic Cancer Correlation With Clinical Features and Carbohydrate Antigen 19-9. Pancreas 2009; 38: 534-541.
9. Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang XS, Parsons DW, Lin JCH, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Cameron JL, Olino K, Schulick R, Winter J, Herman JM, Laheru D, Klein AP, Vogelstein B, Kinzler KW, Velculescu VE and Hruban RH. SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer. Clin Cancer Res 2009; 15: 4674-4679.
10. Skoudy A, Hernandez-Munoz I and Navarro P. Pancreatic ductal adenocarcinoma and transcription factors: role of c-Myc. J Gastrointest Cancer 2011; 42: 76-84.
11. Grippo PJ and Sandgren EP. Acinar-to-ductal metaplasia accompanies c-myc-induced exocrine pancreatic cancer progression in transgenic rodents. Int J Cancer 2012; 131: 1243-1248.
12. Bernstorff WV, Glickman JN, Odze RD, Farraye FA, Joo HG, Goedegebuure PS and Eberlein TJ. Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors-Implications for immune privilege and immune escape. Cancer 2002; 94: 2552-2560.
13. O'Toole SA, McNeil CM, Morey AL, Millar EK, Elena-Lopez-Knowles, Musgrove EA and Sutherland RL. 29. C-Myc Gene Amplification Is Associated With A Poor Prognosis in Invasive Ductal Carcinoma. Pathology-Journal of the RCPA 2010; 42: S89-S90.
14. Wu X, Cai ZD, Lou LM and Zhu YB. Expressions of p53, c-MYC, BCL-2 and apoptotic index in human osteosarcoma and their correlations with prognosis of patients. Cancer Epidemiol 2012; 36: 212-216.
15. Li YJ, Wei ZM, Meng YX and Ji XR. beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: Relationships with carcinogenesis and metastasis. World J Gastroenterol 2005; 11: 2117-2123.
16. Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, Srivastava S and Petrovics G. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis 2010; 13: 311-315.
17. Kanthan R, Fried I, Rueckl T, Senger JL and Kanthan SC. Expression of cell cycle proteins in male breast carcinoma. World J Surg Oncol 2010; 8: 10.
18. He C, Jiang H, Geng S, Sheng H, Shen X, Zhang X, Zhu S, Chen X, Yang C and Gao H. Expression of c-Myc and Fas correlates with perineural invasion of pancreatic cancer. Int J Clin Exp Pathol 2012; 5: 339-346.
19. Lin MS, Chen WC, Huang JX, Gao HJ, Zhang BF, Fang J, Zhou Q and Hu Y. Tissue Microarrays in Chinese Human Rectal Cancer: Study of Expressions of the Tumor-Associated Genes. Hepatogastroenterology 2011; 58: 1937-1942.
20. Ohuchida K, Mizumoto K, Ishikawa N, Fujii K, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M and Tanaka M. The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target. Clin Cancer Res 2005; 11: 7785-7793.
21. Meyer N and Penn LZ. Reflecting on 25 years with MYC. Nature reviews. Cancer 2008; 8: 976-990.
22. Joensuu K, Hagström J, Leidenius M, Haglund C, Andersson L, Sariola H and Heikkilä P. Bmi-1, c-myc, and Snail expression in primary breast cancers and their metastases-elevated Bmi-1 expression in late breast cancer relapses. Virchows Archiv 2011; 459: 31-39.
23. Schleger C, Verbeke C, Hildenbrand R, Zentgraf H and Bleyl U. c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance. Mod Pathol 2002; 15: 462-469.
24. Li YJ, Wei ZM, Meng YX and Ji XR. Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis. World J Gastroenterol 2005; 11: 2117-2123.
25. Naidu R, Wahab NA, Yadav M and Kutty MK. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction. Int J Mol Med 2002; 9: 189-196.
26. Schrader A, Bentink S, Spang R, Lenze D, Hummel M, Kuo M, Arrand JR, Murray PG, Trumper L, Kube D and Vockerodt M. High myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas. Int J Cancer 2012; 131: E348-E361.
27. Hayry V, Makinen LK, Atula T, Sariola H, Makitie A, Leivo I, Keski-Santti H, Lundin J, Haglund C and Hagstrom J. Bmi-1 expression predicts prognosis in squamous cell carcinoma of the tongue. Br J Cancer 2010; 102: 892-897.
28. Macher-Goeppinger S, Bermejo JL, Wagener N, Hohenfellner M, Haferkamp A, Schirmacher P and Roth W. Expression and prognostic relevance of the death receptor CD95 (Fas/APO1) in renal cell carcinomas. Cancer Lett 2011; 301: 203-211.
29. Gryko M, Guzinska-Ustymowicz K, Pryczynicz A, Cepowicz D, Kuklinski A, Czyzewska J, Kemona A and Kedra B. Correlation between Fas and FasL proteins expression in normal gastric mucosa and gastric cancer. Folia Histochem Cytobiol 2011; 49: 142-7.
30. Takikita M, Hu N, Shou JZ, Wang QH, Giffen C, Taylor PR and Hewitt SM. Biomarkers of apoptosis and survival in esophageal squamous cell carcinoma. BMC Cancer 2009; 9: 310.
31. Sejima T, Morizane S, Hinata N, Yao A, Isoyama T, Saito M and Takenaka A. Fas Expression in Renal Cell Carcinoma Accurately Predicts Patient Survival after Radical Nephrectomy. Urol Int 2012; 88: 263-270.
32. Markovic O, Marisavljevic D, Cemerikic V, Perunicic M, Savic S, Filipovic B and Mihaljevic B. Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL). Eur J Haematol 2011; 86: 246-255.